New Pfizer antibiotic, Zavicefta launched in UK

Zavicefta has now been launched in the UK to treat serious aerobic Gram-negative infections caused by antibiotic resistant bacteria. The Pfizer drug is a fixed combination of avibactam, a new beta-lactamase inhibitor, and ceftazidime, an antibiotic belonging to the class of third generation cephalosporins which is already approved for use in the EU.

Continue Reading

New specialised treatments cleared for NHS funding

NHS England announces three new specialised treatments are to be made available on the NHS for patients in England after initial rejection for funding back in December. Funding has been now been approved for second allogeneic haematopoietic stem cell transplants (also known as bone marrow transplants), with around 15 patients a year who suffer a

Continue Reading

NHS files £886 million year to date deficit

Figures published by NHS Improvement shows that NHS provider sector has generated a year-to-date deficit of £886 million, with the sector forecasting a year-end deficit of £873m. According to the regulator, NHS providers are “experiencing one of the most challenging winters on record” due to a huge increase in the demand for urgent and emergency

Continue Reading

MHRA accept Roche’s bladder cancer immunotherapy drug for Early Access to Medicines Scheme

Roche’s Tecentriq has scored another positive opinion. The Medicines and Healthcare products Regulatory Agency (MHRA) has recently accepted the immunotherapy drug into the Early Access to Medicines Scheme (EAMS) for the treatment advanced bladder cancer. The decision means that patients suffering from bladder cancer could have access to the drug while it awaits decision from

Continue Reading

AstraZeneca expands their first line cancer immunotherapy programme

AstraZeneca has expanded a late-stage trial that assess a potential new immuno-oncology (IO) therapy combination for the first-line treatment of non-small cell lung cancer (NSCLC), to include extra endpoints for both the combo and monotherapy. The Phase III MYSTIC trial was originally designed to assess the benefit of durvalumab monotherapy and a combination of durvalumab

Continue Reading